Replies to post #32664 on Ocata Therapeutics Inc fka OCAT

[rocky301]

"The retinal cells may have an advantage when it comes to immune rejection. The space beneath the retina where the cells are injected is generally free of the body's patrolling immune sentries. But in the patients in the trial, the RPE cells have been so damaged by disease that it's not clear whether they continue to maintain their immune-protected cocoon. So just to be safe, the volunteers will be taking drugs to suppress their immune system, in much the same way that patients receiving organ transplants from unrelated donors do."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64342186